Boehringer Ingelheim describes new PHGDH inhibitors
July 11, 2024
Boehringer Ingelheim Pharma GmbH & Co KG has synthesized D-3-phosphoglycerate dehydrogenase (3-PGDH; PHGDH) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, infections and inflammation.